net dbt
busi track expect upsid
esrx deal
strong esrx deal track
ci report adjust ep estimate/ consensu driven
strength global global supplement benefit ci rais
guidanc new guidanc still seem conserv rais midpoint vs
consensu beat meanwhil compani bullish commentari
commerci growth outlook valu proposit esrx deal rais
estim unchang po base ep vs prior
estim reiter buy rate although continu believ
out-performance like come around year end regulatori clariti
ci comfort pbm margin drive valu
despit concern market express script esrx margin might
sustain ci remain confid esrx higher margin peer ci believ
somewhat function mix focus exclus pharmaci vs peer
lower margin busi compani client tend smaller account
buy servic esrx mail order go forward ci believ
abl maintain margin busi pharmaci benefit
manag pbm deliv valu confid combin help
compani deliv averag trend
strong capit posit pf
expect capit deploy spent debt
repo pf greater allow ci delev high debt cap
within month leav capit avail deploy item
estim least prioriti remain reinvest busi repo
fischbeck focu esrx deal rational accret
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu strateg rational accret cash flow
benefit esrx deal deal took market surpris investor
focus potenti horizont deal howev see valu integr
healthcare/pbm model view benefit quit attract
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
one largest provid manag
care servic us origin properti
casualti insur compani found
larg focus healthcar
busi offer hmo indemn product
well meaning intern life
ci core busi continu improv creat
averag earn growth prospect
addit upsid capit deploy
fischbeck focu section choos theme explor detail either
respons recent investor question unexpect develop
quarter quarter focu strateg rational accret cash flow
benefit esrx deal deal took market surpris investor
focus potenti horizont deal howev see valu integr
healthcare/pbm model view benefit quit attract
strateg merit deal
market surpris esrx deal percept came
togeth somewhat quickli ci refut idea highlight deal
defens reaction ci receiv offer outreach third parti
relat acquisit ci instead main driver deal drive
afford current health care trend trajectori unsustain ci goal
drive medic pharmaci trend cpi believ deal
put track notabl ci employ clinician esrx employ
clinician togeth compani could deliv attract product offer
control cost addit ci highlight overlap ci nation account
carv esrx would substanti opportun build
relationship creat new servic divis help combin compani grow
faster simpli averag two compani growth rate
manag trend rang cpi
medic cost trend manag care trend health servic trend
stand-alone ci trend meanwhil ci see potenti esrx deal
lower medic pharmaci trend level consum price cpi
result annual save ci highlight predict analyt capabl
coordin care treatment program align incent value-bas
model key lever achiev save target overal target underscor
core rational deal deliv afford health insur custom
specialti pharmaci item must control
compon trend specialti pharmaci perhap grow quickest
ci expect tripl next year result compani go
deliv averag trend must make inroad around specialti trend compani
believ esrx scale specialti also number clinic program
help reign specialti pharmaci cost
close gap care
last major piec around control cost manag gap care although ci
gain scale pharmaci purchas buy esrx alreadi get good deal
unit cost much increment save outsid
specialti purchas drug instead benefit around better
leverag million custom data point interact member
year fill prescript compani believ inform
allow better identifi close gap care
ci highlight esrx deal immedi accret deliv mid-
teen accret first full year post close exclud contribut esrx
transit client exclud revenu synergi
show accret analysi ci-esrx deal analysi assum
compani pay debt success return pf debt cap ratio
month post close line compani commentari addit
assum compani renew share repurchas overal estim ci pf
esrx could earn toward high end manag target rang
account revenu synergi
pf ni synergi
pf ep synergi
pf ep synergi
pf possibl compel part deal
ci expect strong pf free cash flow nearli estim ci
stand-alone strong free cash flow capit deploy option posit ci
well continu innov dynam health care sector appear achiev
estim ci pf esrx could gener note ci/esrx
would gener amount continu servic
creat extra one-tim cash benefit coupl billion dollar includ
accret analysi
chart ci-esrx pf
view cash flow put leagu larger player space
health/aetna creat separ
clear next area capit focu
ci would abl make necessari invest
initi next lever drive trend
gener investor see strateg rational behind deal
pushback tend around whether better potenti use capit
addit investor acknowledg ci sell manag care servic
esrx pharmaci support probabl better ci sell manag care servic
addit acknowledg esrx sell pbm servic alongsid ci
better esrx sell alon question come ye esrx/ci better
esrx would would esrx much
accret pf argument start fade away esrx gener billion
billion ebitda instead billion
question aris market remain concern sustain pbm
margin gener esrx margin particular increas focu price
transpar rebat suppli chain risk either market forc
potenti new regul could lead margin compress concern especi
acut esrx averag margin lose largest
custom acknowledg make averag margin
despit concern market esrx margin might sustain ci
remain confid esrx higher margin peer ci believ
somewhat function mix focus exclus pharmaci vs peer
lower margin busi compani client tend smaller account buy
servic esrx mail order go forward ci believ
abl maintain margin busi pbm deliv valu
confid combin help compani deliv averag trend
meanwhil note pbm servic wrap within manag care product
appear less suscept margin pressur caus transpar issu straight
pbm contract provid make fee per script earn rebat drug spend
compani make money matter degre howev within risk
product custom pay flat per member per month rate offload health
care cost trend risk manag care organ less import
make money provid drug etc point
matter employ benefit cheapest benefit provid
final fact ci receiv offer outreach third parti relat
acquisit ci bode well amid concern compani pursu esrx deal
defens move make sharehold vote straightforward
also allay concern ci rush due dilig esrx didnt fulli
appreci pbm industri pressur
conclus mco track buy ci valuat
overal fundament remain solid continu expect beat rais
throughout year meanwhil continu view ci attract risk/reward
compani current trade ep pro forma esrx deal
attract price see clear valu integr model view accret
target achiev reiter buy
ci rais adjust ep guidanc midpoint
relat favor develop impli ep growth year
year guidanc rais appear conserv given beat
ci rais low end membership growth outlook member
could part due exchang growth
compani increas consolid adjust incom oper
billion previou guidanc rais driven global
health midpoint global supplement benefit
corporate/oth meanwhil group disabl life
adjust incom oper outlook remain unchang impli stabil
govern medic loss ratio outlook lower basi point
expect driven strong perform busi ci
re-affirmed guidanc commerci healthcar oper expens ratio
compani reiter view cost trend would vs
y/i increas due higher util pharmaci cost pharmaci trend
see anyth unusu around acuiti
compani re-affirmed adjust tax rate continu expect annual
consolid revenu growth
note guidanc exclud impact addit futur capit
group disabl
incom loss
incom loss
po base ep estim repres premium
five-year averag view appropri given outlook
risk po issu disabl life busi compani see higher
expect cost trend potenti impact futur regulatori chang star
rate continu deterior
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
